Key Highlights
- SelectQuote (NYSE:SLQT) appears on the aggressive small cap screen with a one-year EPS change of 159.38% and a Market Value of about USD 81 million, at USD 0.45 in the November 13 snapshot, down 7.53% on the session.
- Fiscal first quarter Revenue fell 14.8% to USD 280.0 million, while the net loss narrowed to USD 20.3 million and the adjusted EBITDA loss shrank to USD 17.0 million from USD 32.1 million.
- Healthcare Services adjusted EBITDA rose 56% to USD 11.2 million as profit per SelectRx member climbed 60%, even as membership fell 7% to 99,753.
- Full-year fiscal 2027 guidance was reiterated at revenue of USD 1.35 billion to USD 1.45 billion and adjusted EBITDA of USD 90 million to USD 115 million.
A Seasonal Quarter With Better Unit Economics
SelectQuote reported its fiscal first quarter, the three months to September 30, on November 4. The quarter is seasonally its weakest because Medicare enrolment activity peaks later in the year. Consolidated revenue was USD 280.0 million against USD 328.8 million, and the net loss narrowed to USD 20.3 million from USD 30.5 million. The adjusted EBITDA loss shrank to USD 17.0 million from USD 32.1 million, and operating cash use eased to USD 17.2 million. The Senior insurance segment, which sells Medicare Advantage plans, earned revenue of USD 50.8 million, down 14%, with approved policies down 18% to 50,976, but its adjusted EBITDA loss narrowed to USD 12.3 million from USD 21.0 million as the company focused on more profitable sales. The Life segment improved adjusted EBITDA to USD 7.3 million. The shares rose about 19.9% on the day of the release, showing that investors welcomed the narrower losses.
SelectRx and the Path to Profit
Healthcare Services, built around the SelectRx pharmacy that delivers medicines to Medicare members, is now the main profit engine. Its revenue fell 16% to USD 186.3 million, and members declined 7% to 99,753, but adjusted EBITDA rose 56% to USD 11.2 million as profit per member increased 60% to about USD 107.6. The strategy has shifted from adding members at any cost to serving them more profitably. Management also reports a revenue to customer Acquisition cost multiple of 7.0 times over twelve months, up from 6.4 times. The screen's one-year EPS change of 159.38% reflects improvement from a deep loss and should not be read as a sign of consistent profitability. Loss per share was USD 0.21 against USD 0.26 a year earlier, and fiscal 2026 included both profitable and loss-making quarters, so the annual swing depends heavily on the fourth calendar quarter enrolment season.
Balance Sheet and Listing Risk
The Capital Structure is the main concern. Debt carried at about USD 385.8 million sits alongside senior non-convertible preferred stock with a Liquidation preference of about USD 438.6 million, while cash was only about USD 13.4 million at September 30. A refinanced USD 415 million Credit Facility completed in March extended most maturities to 2031, which removes a near term wall. The share price is a separate risk. In March, the NYSE notified the company that its average closing price had fallen below USD 1.00 over 30 trading days, starting a six-month cure period, and the stock remains well below that level. The outcome of that process has not been confirmed in the material reviewed, so investors should watch for any reverse split proposal or further notice. Delivery of the guided USD 90 million to USD 115 million of adjusted EBITDA and over USD 60 million of Operating Cash Flow is the key to easing both issues.
Where Things Stand
SelectQuote (NYSE:SLQT) is narrowing losses and earning more from each SelectRx member, and it kept its full-year targets. A heavy debt and preferred stack, thin cash and a share price below USD 1 keep the risk high. The coming Medicare enrolment season will largely decide fiscal 2027.






Please wait processing your request...